Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA in Metastatic CRPC June 2, 2026
HREC Australia approves HLX3902 for Clinical Trial in Australia in metastatic CRPC and other advanced solid tumours May 26, 2026
Ph 2 ARASEC Data Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic CSPC May 21, 2026
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic HSPC May 21, 2026
Extended Clinical Benefit Over Multiple Clinical Endpoints Reported from Ph 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at longer Follow-up May 21, 2026
Rinzimetostat RP3D in Combination with Darolutamide selected for Himalayas-1 Ph 3 Global Study with Dose Optimization Data April 7, 2026
TALZENNA Plus XTANDI Significantly Improves Radiographic PFS in Metastatic Prostate Cancer March 24, 2026
ProstACT Ph 3 Study (Part 1) of TLX591-Tx Achieves Primary Objectives in PSMA+ve metastatic CRPC Patients March 17, 2026
European Commission approves AKEEGA (niraparib & abiraterone dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic HSPC patients March 10, 2026
Encouraging results for 225Ac-PSMA-Trillium in advanced metastatic prostate cancer reported March 3, 2026
Astellas and Vir Biotechnology to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer March 3, 2026
New real‑world data reinforce earlier use of Pluvicto before chemotherapy in metastatic CRPC March 3, 2026
Early study results show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer March 3, 2026
Candel Therapeutics’ $100M Royalty Funding Agreement with RTW to Support Aglatimagene Besadenovec (CAN-2409) Launch in Localized Prostate Cancer Announced February 25, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 1, 2026
Preliminary Results from Ph 2 Study of PDS01ADC in 3L Metastatic CRPC by the NCI to be presented February 1, 2026
CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for metastatic HSPC with BRCA1/2 mutations February 1, 2026
First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland Announced December 30, 2025
Clinical Activity of MRT-2359 + Enzalutamide Combo in Heavily Pretreated Metastatic CRPC Patients with Androgen Receptor Mutations Announced December 22, 2025
FDA approves AKEEGA® for BRCA2m metastatic CSPC with 54% reduction in disease progression vs SOC December 15, 2025
